A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia - Join Clinical Trial NCTNCT03655678
How to Join This Clinical Trial - NCTNCT03655678
Learn how to participate in this PHASE2, PHASE3 trial studying an investigational therapy for Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn, Hematologic Diseases, Hemoglobinopathies. Current status: ACTIVE_NOT_RECRUITING.
Am I Eligible for This Clinical Trial?
This clinical research study is looking for participants with Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn, Hematologic Diseases, Hemoglobinopathies. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.
- Condition Being Studied
- Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn, Hematologic Diseases, Hemoglobinopathies
- Treatment Being Tested
- Investigational treatment
- Study Phase
- PHASE2, PHASE3 - Large-scale efficacy study
- Enrollment Status
- ACTIVE_NOT_RECRUITING
- Study Identifier
- NCTNCT03655678 - ClinicalTrials.gov Identifier
- Sponsored By
- Study sponsor
What to Expect as a Participant
Participating in this clinical trial involves:
- Initial screening to determine eligibility
- Regular study visits and health assessments
- Receiving the study treatment or placebo
- Medical monitoring and follow-up care
- Contributing to medical research that may help others
- Potential access to new treatments before they're widely available
Clinical Trial Benefits and Compensation
Participants in this clinical research study may receive:
- Close medical monitoring by healthcare professionals
- Access to potential new treatments
- Compensation for time and travel (varies by study)
- No-cost study-related medical care
- The opportunity to help advance medical knowledge
Where Is This Clinical Trial Located?
This study is enrolling participants at 14 locations. Find a study site near you:
Clinical Research Site
Palo Alto, California 94304 - United States
Status: Contact for availability
Clinical Research Site
Chicago, Illinois 60611 - United States
Status: Contact for availability
Clinical Research Site
New York, New York 10032 - United States
Status: Contact for availability
Clinical Research Site
New York, New York 10032 - United States
Status: Contact for availability
Clinical Research Site
Philadelphia, Pennsylvania 19104 - United States
Status: Contact for availability
Clinical Research Site
Nashville, Tennessee 37203 - United States
Status: Contact for availability
Clinical Research Site
Toronto, - Canada
Status: Contact for availability
Clinical Research Site
Vancouver, - Canada
Status: Contact for availability
Clinical Research Site
Düsseldorf, - Germany
Status: Contact for availability
Clinical Research Site
Regensburg, - Germany
Status: Contact for availability
And 4 more locations available. Contact us to find the nearest participating site.
How to Enroll in This Study
To learn more about participating in this PHASE2, PHASE3 clinical trial for Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn, Hematologic Diseases, Hemoglobinopathies:
- Review the eligibility criteria with your healthcare provider
- Contact the study team for a pre-screening interview
- Schedule an in-person screening visit if eligible
- Review and sign the informed consent form
- Begin participation in the clinical trial
Why Choose Quri.ai Study Finder
Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:
- Discover clinical trials before competitors
- Access exclusive contact information
- Track sponsor pipelines and opportunities
- Connect with decision makers directly
- Win more business partnerships